Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Vigushin

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|June 1, 2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trialAndreas Polychronis, H Dudley Sinnett, Dimitri Hadjiminas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitorSusannah J Stanway, Atul Purohit, L W Lawrence Woo, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|June 1, 2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trialAndreas Polychronis, H Dudley Sinnett, Dimitri Hadjiminas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitorSusannah J Stanway, Atul Purohit, L W Lawrence Woo, et al.
Pageof 1